Treatment of Recurrent or High-Risk Basal Cell Carcinoma

Certain clinical and histopathological features place a basal cell carcinoma in a high-risk category that requires a distinct treatment strategy. This protocol addresses those presentations specifically.

Clinical Scenario
  • Recurrent basal cell carcinoma
  • Aggressive histopathological subtype
  • Located on a critical anatomical site
  • Poorly defined margins
  • Perineural invasion
  • Multiple basal cell carcinomas
Treatment Approach

For high-risk BCC presentations, the protocol includes an oral hedgehog pathway inhibitor as a systemic treatment option. The specific agent, selection criteria, and full management details are available in the complete protocol below.

References

DOI: 10.1016/j.ejca.2023.113254

  • Micrographically controlled surgery shall be offered in high-risk and recurrent BCC, and BCC located on critical anatomical sites.
  • Micrographically controlled surgery (3D) shall be offered in high-risk BCC (recurrent, aggressive subtypes, location in critical anatomical sites, poorly defined margins)
  • Hedgehog inhibitors should be offered to patients with locally advanced or metastatic BCC
View source ↗